MetrioPharm

Executive Summary

MetrioPharm is a Swiss biopharmaceutical company pioneering small molecule therapeutics that modulate macrophage function to treat chronic inflammatory and fibrotic diseases. Founded in 2008 and headquartered in Zürich, the company leverages a deep understanding of immune cell biology to develop first-in-class oral drugs aimed at resolving inflammation without immunosuppression. Its lead asset, MP1032, has completed Phase 1 studies and is being evaluated in Phase 2 trials for psoriasis and other inflammatory conditions. Preclinical data suggest MP1032 may also have potential in fibrotic indications such as non-alcoholic steatohepatitis (NASH). Despite limited public disclosure, MetrioPharm's novel mechanism and early clinical data position it as a promising player in the anti-inflammatory space. The company faces typical development risks but benefits from a focused strategy and experienced management.

Upcoming Catalysts (preview)

• Q3 2026Phase 2a top-line data for MP1032 in psoriasis50% success
• Q1 2027Initiation of Phase 2b trial in NASH40% success